Skip to main content

7 Result(s)

within Paolo Antonio Ascierto Remove this filter Medicine & Public Health Remove this filter Cancer Research Remove this filter Oncology Remove this filter

and

  1. Article

    Open Access

    Impact of cemiplimab treatment duration on clinical outcomes in advanced cutaneous squamous cell carcinoma

    Treatment duration with checkpoint inhibitors must be optimized to prevent unjustified toxicity, but evidence for the management of cutaneous squamous cell carcinoma is lacking. A retrospective study was perfo...

    Domenico Mallardo, Francesca Sparano… in Cancer Immunology, Immunotherapy (2024)

    Download PDF (1491 KB) View Article

  2. Article

    Open Access

    Melanoma-derived soluble mediators modulate neutrophil biological properties and the release of neutrophil extracellular traps

    Polymorphonuclear neutrophils (PMNs) are the main effector cells in the inflammatory response. The significance of PMN infiltration in the tumor microenvironment remains unclear. Metastatic melanoma is the mos...

    Luca Modestino, Leonardo Cristinziano… in Cancer Immunology, Immunotherapy (2023)

    Download PDF (3278 KB) View Article

  3. No Access

    Article

    A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients

    Engineered cytokine products represent promising agents for the treatment of immunogenic tumors, such as malignant melanoma, in addition to immune checkpoint inhibitors. Here we describe the results of a contr...

    Benjamin Weide, Thomas Eigentler, Chiara Catania… in Cancer Immunology, Immunotherapy (2019)

  4. No Access

    Article

    Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study

    CTLA-4 blockade by means of ipilimumab (IPI) potentiates the immune response and improves overall survival (OS) in a minority of metastatic melanoma (MM) patients. We investigated the role of soluble CTLA-4 (s...

    Maria Pia Pistillo, Vincenzo Fontana, Anna Morabito… in Cancer Immunology, Immunotherapy (2019)

  5. No Access

    Article

    Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5–7, 2012

    Michele Maio, Hugues Jean Marie Nicolay… in Cancer Immunology, Immunotherapy (2013)

  6. No Access

    Article

    Inhibitory effects of anti-CXCR4 antibodies on human colon cancer cells

    Background: CXCR4, the chemokine receptor for CXCL12, has recently been involved in the metastatic process of several neoplasms. Materials and methods: The expression of CXCR4 was evaluated by immunohistochemistr...

    Alessandro Ottaiano, Antonella di Palma… in Cancer Immunology, Immunotherapy (2005)

  7. No Access

    Article

    Prospective clinical trials of biotherapies in solid tumors: a 5-year survey

    Purpose: To review the content and quality of prospective clinical trials of biotherapies in solid tumors. Methods: Data were collected from the literature between 1990 and 2002 on general study characteristic...

    Alessandro Ottaiano, Ernesto Mollo, Giuseppe Di Lorenzo… in Cancer Immunology, Immunotherapy (2005)